CN103048454A - Nanometer magnetic particle chemiluminescence detection kit for hepatitis B virus e antigen as well as preparation method thereof and detecting method thereof - Google Patents
Nanometer magnetic particle chemiluminescence detection kit for hepatitis B virus e antigen as well as preparation method thereof and detecting method thereof Download PDFInfo
- Publication number
- CN103048454A CN103048454A CN2012105501727A CN201210550172A CN103048454A CN 103048454 A CN103048454 A CN 103048454A CN 2012105501727 A CN2012105501727 A CN 2012105501727A CN 201210550172 A CN201210550172 A CN 201210550172A CN 103048454 A CN103048454 A CN 103048454A
- Authority
- CN
- China
- Prior art keywords
- virus
- hepatitis
- antigen
- antibody
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention relates to a nanometer magnetic particle chemiluminescence detection kit for a hepatitis B virus e antigen as well as a preparation method thereof and a detecting method thereof. The kit comprises a solution, which contains a fluorescein labeled hepatitis B virus e antigen antibody, a suspension, which is coated with magnetic particles of a fluorescein antibody, and a solution, which contains an alkaline phosphatase labeled hepatitis B virus e antigen antibody. According to the invention, the hepatitis B virus e antigen can be quantitatively detected with lower cost, higher accuracy and higher precision.
Description
Technical field
The invention belongs to biological technical field, be specifically related to a kind of nano magnetic particulate chemistry luminescence assays kit and preparation method thereof and detection method of the hepatitis B virus e antigen that combines immune magnetic particle isolation technics and chemiluminescence immunoassay technology.
Background technology
Hepatitis B virus e antigen (HBeAg) is to have a kind of soluble protein in the HBV core with hidden form, and its encoding gene is overlapped, is the subcomponent of HBcAg.After infecting HBV, HBeAg can or come across in the blood after a while with the HBsAg while, and it disappears then a little earlier in HBsAg.HBsAg exists only in the blood of HBsAg positive, usually with the copying of HBV DNA in the liver, exists more Dane particle and HBV dna polymerase activity to increase in the blood, and therefore, the HBeAg positive is the important indicator that viral activity copies, and infectiousness is high.If more than 10 weeks of oxyhepatitis patient HBeAg lasting masculin, then be easy to transfer to persistent infection.
Immune analysis method for detection of hepatitis B virus e antigen mainly contains enzyme-linked immunosorbent assay, chemiluminescence immunoassay etc. at present.The methodology limiting factors such as enzyme-linked immunosorbent assay exists sensitivity low, and narrow, the difficult realization of the range of linearity is full-automatic.Chemiluminescence immunoassay is a kind of immunoassay technology that grows up on the enzyme-linked immunosorbent assay basis, have highly sensitive, detect the advantages such as linear wide ranges, easy and simple to handle, automaticity height.Chemiluminescence immunoassay technology is widely used because it has above-mentioned plurality of advantages at present.
Yet, in the immune detection of reality, owing to impurity component contained in the testing sample is more, detection sensitivity and accuracy have been affected to a certain extent, so from the sample substrate of complexity, separate fast, be purified into the purpose determinand, it is one of difficult problem of facing of clinical examination worker.
The magnetic particle immunoassay technology is to utilize the magnetic solid phase particle of synthesis of polymer material certain particle size size to make carrier, have the various immunologic active materials such as the antibody of specificity affinity or antigen on coated with methods such as physisorption, chemical couplings, have that velocity of separation is fast, efficient is high, the characteristics such as favorable repeatability, simple to operate, the biological character that do not affect separated cell or other biological material and function, adding orientable motion under the magnetic fields, so that some special composition is separated, concentrated or purifying.
Summary of the invention
Technical matters to be solved by this invention is to overcome the deficiencies in the prior art; a kind of nano magnetic particulate chemistry luminescence assays kit of hepatitis B virus e antigen is provided; it can prepare with lower cost, and can realize the accurate and high precision ground quantitative measurement of hepatitis B virus e antigen.
The present invention also provides a kind of preparation method of nano magnetic particulate chemistry luminescence assays kit of hepatitis B virus e antigen simultaneously, the method process stabilizing, and cost is low, and the precision of gained kit is high.
The kit that cancer antigen is used easy and preparation method cheaply.
The nano magnetic particulate chemistry luminescence assays kit of a kind of hepatitis B virus e antigen (HBeAg) is characterized in that this kit comprises:
The first reagent: the solution that contains fluorescein-labeled hepatitis B virus e antigen antibody;
The second reagent: the solution that contains the hepatitis B virus e antigen antibody of alkaline phosphatase (ALP) mark;
Magnetic separating agent: the suspending liquid that contains the magnetic particle of coated fluorescein antibody.
Preferably, the hepatitis B virus e antigen antibody of this alkali phosphatase enzyme mark passes through crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester (Succinimidyl 4-(N-Maleimidomethyl) Cyclohexane-1-Carbo by alkaline phosphatase and hepatitis B virus e antigen antibody, SMCC) and 2-imino group sulfane hydrochloride (2-Iminothiolane HCl, 2-IT) connect and compose.
Further, in the described magnetic particle reagent, the magnetic particle that is coated with fluorescein antibody passes through the coupling of coupling agent phase chemistry by fluorescein antibody and magnetic particle.
Further, the concentration of the fluorescein-labeled hepatitis B virus e antigen antibody in described the first reagent is 0.5 ~ 1 μ g/mL, and the pH of described the first reagent is 7-9; The concentration of the hepatitis B virus e antigen antibody of the alkali phosphatase enzyme mark in described the second reagent is 0.5 ~ 1 μ g/mL, and the pH of described the second reagent is 7-9.
Those skilled in the art should know, and kit of the present invention can further include other and detects required reagent, for example substrate solution.But can buy separately or prepare such as other reagent such as substrate solutions, therefore, although can comprise these reagent in the kit, they be not essential for kit of the present invention.
The another technical scheme that the present invention takes is: a kind of preparation method of nano magnetic particulate chemistry luminescence assays kit of above-mentioned hepatitis B virus e antigen; it comprises the step for preparing respectively described the first reagent, described the second reagent and magnetic separating agent, and wherein: the preparation process of described the second reagent is as follows:
1. with after room temperature leaves standstill in the hepatitis B virus e antigen antibody adding crosslinking chemical 2-imino group sulfane hydrochloride solution, add glycine solution, room temperature leaves standstill again, collects the hepatitis B virus e antigen antibody after activating, and saves backup under 2 ~ 8 ℃ again;
2. the alkaline phosphatase enzyme solutions is added crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill, and collects the alkaline phosphatase after activating, and saves backup under 2 ~ 8 ℃;
3. with above-mentioned steps 1. the alkaline phosphatase of the hepatitis B virus e antigen antibody after the gained activation after 2. gained activates with step mix, leave standstill reaction, make the hepatitis B virus e antigen antibody that generates alkali phosphatase enzyme mark, after reaction finishes, with reactant liquor Supperdex200 gel-purified post purifying, damping fluid adjustment concentration and the pH value selecting to have proper pH value namely get described the second reagent;
Wherein, the purity of described hepatitis B virus e antigen antibody, described alkaline phosphatase is all more than or equal to 95wt%, and the specific activity of described alkaline phosphatase surpasses 1000u/mg.
Preferably, step 1. in, get hepatitis B virus e antigen antibody, add the dissolving of crosslinking chemical 2-IT solution, room temperature leaves standstill 10min ~ 30min, adds glycine solution, room temperature leaves standstill 2 ~ 10min, with G-25 gel-purified post desalination, collect the hepatitis B virus e antigen antibody after activating, save backup in 2-8 ℃.
Preferably, step 2. in, get concentration more than or equal to the alkaline phosphatase enzyme solutions of 5mg/mL, add crosslinking aid S MCC solution, room temperature leaves standstill 20 ~ 40min, with G-25 gel column desalination, collects alkaline phosphatase after the activation, saves backup in 2-8 ℃.
Preferably, step 3. in, be that 1:1 ~ 1:2 mixes with the alkaline phosphatase of the hepatitis B virus e antigen antibody of above-mentioned activation and activation by the molecule mol ratio, under 2-8 ℃ of condition, leave standstill 12-24h.
Wherein the damping fluid of proper pH value can be for for example containing the TRIS damping fluid of 0.5% bovine serum albumin(BSA), pH8.0.
Further, the preparation method of described the first reagent is as follows: the pH that preparation contains fluorescein is 9 ~ 10 damping fluid, then the molecular proportion according to fluorescein and hepatitis B virus e antigen antibody is the ratio of 20 ~ 200:1, be 9 ~ 10 damping fluid with the described pH that contains fluorescein with the pH of hepatitis B virus e antigen antibody be that 9 ~ 10 damping fluid mixes, behind the mixing, room temperature leaves standstill reaction, then reactant liquor is separated by the G-25 gel column, remove free fluorescein, obtain containing the solution of fluorescein-labeled anti-hepatitis B virus e antigen-antibody, then adjust concentration and pH with the damping fluid with proper pH value, namely get described the first reagent.Wherein the damping fluid of proper pH value can be for for example containing the TRIS damping fluid of 0.5% bovine serum albumin(BSA), pH8.0.
Further, the preparation method of described magnetic separating agent is as follows: will contain the magnetic particle of carboxyl reactive group and fluorescein antibody in the presence of the coupling agent carbodiimide, room temperature reaction 2 ~ 18 hours, reaction finishes, magnetic separates, remove supernatant, adjust pH and concentration with the damping fluid with proper pH value, namely get described magnetic separating agent.Wherein said magnetic particle has superparamagnetism, and its diameter is 0.5 ~ 2 μ m, on every gram magnetic particle with the content of carboxyl reactive group be not less than 0.4mmol; Described fluorescein antibody is monoclonal antibody or polyclonal antibody, and purity is more than or equal to 90wt%, and dilution is tired greater than 1:100 ten thousand.
Preferably, the above-mentioned damping fluid with proper pH value is the TRIS damping fluid that contains 0.5% bovine serum albumin(BSA), pH8.0.
Fluorescein of the present invention can be known various fluoresceins, and commonly used have for example fluorescein isothiocynate, RB 200, a TRITC etc.
The present invention also provides simultaneously a kind of and has adopted above-mentioned kit to be applied to the detection method that hepatitis B virus e antigen quantitatively detects, and it is characterized in that, may further comprise the steps:
(1) immune response: add sample to be tested stoste in detector tube, add successively the first reagent and the second reagent, mixing carries out the incubation first time under 25 ~ 40 ℃, then add the magnetic separation agent, and mixing carries out the incubation second time under 25～40 ℃;
(2) washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add cleaning fluid, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant;
(3) add substrate solution and detect luminous intensity: in detector tube, add the chemical luminous substrate of alkaline phosphatase enzymatic, remove magnetic field, fully detect luminous intensity values behind the suspendible.
Further, the time of the incubation first time described in the step (1) can be 10 ~ 40min, is generally 30min; The time of incubation can be 5～20min for the second time, is generally 10min.
Because the enforcement of above technical scheme, the present invention compared with prior art has following advantage:
1. the applicant finds, when taking SMCC and 2-IT to carry out the coupling of alkaline phosphatase and hepatitis B virus e antigen antibody as crosslinking chemical, has with other crosslinking chemical and compares higher coupling efficiency, when reducing preparation cost, is conducive to improve the detection effect.Therefore, three kinds of reagent in the kit of the present invention all can prepare by stable preparation technology, and production cost is low, and because preparation technology's stability, it is little that kit is analyzed differences between batches, and precision improves between the analysis of detection;
2. the preparation method of the solution of the hepatitis B virus e antigen antibody that contains alkali phosphatase enzyme mark in the kit of the present invention, can be effectively with hepatitis B virus e antigen antibody and alkaline phosphatase coupling, coupling efficiency is high, and it is low and guarantee the detection effect of kit further to reduce the cost of kit.
3, take kit of the present invention to detect, accuracy is good, and precision is high, and highly sensitive, sensing range is wide, and sample need not pre-dilution, simple to operate saving time.Compare with the method that adopts the import reagent box to detect, detection method of the present invention has significant advantage at cost.
Description of drawings
Fig. 1 is detection calibration product typical curves;
Fig. 2 is that matched curve is estimated in sensitivity;
Fig. 3 is serum sample testing result correlativity (wherein horizontal ordinate x is the kit sample measured value that embodiment 4 is prepared into, and concentration unit is U/mL, and ordinate y is Diasorin company kit sample measured value, and concentration unit is U/mL).
Embodiment
The preparation of embodiment 1 first reagent
(1) material and instrument: with the hepatitis B virus e antigen monoclonal antibody (purity surpasses 95wt%, and concentration is 2mg/mL) of phosphate buffer preservation; Fluorescein isothiocynate (FITC), the reagent such as sodium carbonate should reach chemical pure; The buying of G-25 gel-purified post is from GE company.
(2) preparation process:
1. use the FITC solution of the carbonate buffer solution preparation 0.5mg/mL of 0.1 ~ 0.2mol/L pH 9.0 ~ 10.0;
2. add step according to hepatitis B virus e antigen antibody and FITC molecular proportion by the ratio of 1:20 in antibody-solutions and 1. joined FITC solution, mix, room temperature left standstill 12h hour, and reaction generates e antigen-antibody-FITC connector;
3. will separate by the G-25 gel column through step reactant liquor 2., remove unreacted FITC, obtain containing the solution of hepatitis B virus e antigen antibody-FITC connector (being the hepatitis B virus e antigen antibody of FITC mark);
4. with step 3. the gained solution that contains hepatitis B virus e antigen antibody-FITC connector to be diluted to hepatitis B virus e antigen antibody-FITC connector concentration with the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH 8.0 be 0.5 ~ 1 μ g/mL, be the first reagent.
The preparation of embodiment 2 second reagent
(1) material and instrument: with the hepatitis B virus e antigen monoclonal antibody (purity surpasses 95wt%, and concentration is 2mg/mL) of phosphate buffer preservation; The alkaline phosphatase of preserving with phosphate buffer (ALP solution, ALP purity are about 99%, and specific activity is about 1500U/mg, and concentration is 10mg/mL); Crosslinking aid S MCC, 2-IT is available from THERMO company, and the chemical reagent such as TRIS should reach chemical pure; G-25 gel-purified post is GE company product.
(2) preparation process:
1. get 1mg e antigen-antibody, add the coupling agent 2-IT solution 2-4 μ L of 10mg/mL, room temperature leaves standstill 20min, add the glycine solution 10 μ L of 0.1mol/L, room temperature leaves standstill 5min, with G-25 gel column desalination, collect the rear CA125 antibody of activation, 2-8 ℃ saves backup;
2. get the ALP solution of 1.5mg, add the SMCC solution 10-20 μ L of 5mg/mL, room temperature leaves standstill 30min, with G-25 gel column desalination, collects the rear ALP of activation, and 2-8 ℃ saves backup;
3. the cancer antigen e antigen-antibody with above-mentioned activation mixes with the ALP of activation, leaves standstill 12-24h under the 2-8 ℃ of condition, with Supperdex200 gel-purified post purifying conjugate, obtains CA125 antibody-ALP connector strong solution, and 2-8 ℃ saves backup;
4. use the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH8.0 to be diluted to 0.5-1 μ g/mL e antigen-antibody-ALP connector strong solution, finish the preparation of the second reagent.
The preparation of embodiment 3 magnetic separation agents
(1) material and instrument:
The suspending liquid of magnetic particle: magnetic particle content 5wt%, magnetic particle contain the active group of carboxyl (COOH), and every gram (g) magnetic particle (dry weight) carboxyl-content is not less than 0.4 mM (mmol), has superparamagnetism, and diameter is between 0.5-2 μ m.
Anti-FITC mAb: can be polyclonal antibody, also can be monoclonal antibody, and purity is more than the 90wt%, and dilution is tired above 1:100 ten thousand;
MES (MES), carbodiimide (EDC), TRIS and other reagent should reach chemical pure.
(2) preparation process:
1. get the suspending liquid of 100mg magnetic particle, magnetic divides the supernatant of leaving away, and uses 0.05mol/L, and 10mL is resuspended for pH 4.5 ~ 5MES damping fluid;
2. the anti-FITC mAb that adds 2 ~ 4mg, room temperature suspendible 30 ~ 60min;
3. the EDC aqueous solution that adds the freshly prepared 10mg/mL of 0.5 ~ 1mL, room temperature suspendible 2 ~ 12h;
4. magnetic separates, and removes supernatant, uses the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH 8.0 to be resuspended to 1mg/mL, and pH 8.0, are the magnetic separation agent.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 4 hepatitis B virus e antigens
This kit comprises:
According to first reagent (concentration is 0.75 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 0.75 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 5 hepatitis B virus e antigens
This kit comprises:
According to first reagent (concentration is 0.5 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 0.5 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 6 hepatitis B virus e antigens
This kit comprises:
According to first reagent (concentration is 1 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 1 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
Embodiment 7 takes the kit of embodiment 4 to carry out the quantitative detection of hepatitis B virus e antigen
(1) detecting step:
1. immune response: in detector tube, add 30 μ L sample to be tested (serum) stostes, then add 50 μ L the first reagent, 50 μ L the second reagent, mixing, incubation 30min under 37 ± 1 ℃ of conditions; Add 50 μ L magnetic separation agents, mixing, incubation 10min under 37 ± 1 ℃ of conditions;
2. washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add the cleaning fluid of 300 μ L, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant; This step repeats 3 times;
3. add substrate solution and detect luminous intensity: add 100 μ L alkaline phosphatase chemical luminous substrate solution (Beijing Ah APCL-of this Bioisystech Co., Ltd I) in detector tube, concussion makes the abundant suspendible of magnetic particle, detects luminous intensity in 5min.
(2) draw the calibration object typical curve
The calibration object typical curve is referring to Fig. 1.
(3) sensitivity evaluation
Detect " 0 " concentration samples, duplicate detection 20 times, calculate mean value (M) and the standard deviation (SD) of relative luminous intensity (RLU), and calculating M+2SD value, carry out 2 regression fits according to the concentration-RLU between zero-dose calibration object and the adjacent calibration object and draw linear function, the M+2SD value is brought in the above-mentioned equation, obtain corresponding concentration value, be lowest detectable limit.The sensitivity of this method is not less than 2U/mL.Wherein: A point luminous value is respectively referring to table 1:
Table 1
The luminous average X=553 of A point
SD=32
X+2SD=616
B point luminous value is respectively referring to table 2.
The luminous average X=12311 of B point
Table 2
| HBeAg-STD-B(RLU) |
| 12365 |
| 12256 |
A, B point connect the some matched curve referring to Fig. 2.Sensitivity=0.003U/mL.
(4) precision evaluation
1. precision in analyzing
The kit of embodiment 4 is a collection of, measure respectively the serum of basic, normal, high three kinds of variable concentrations, 10 hole replicate determinations, the result is referring to table 3, and drawing the variation within batch coefficient is 4.12%～5.69%.
Precision test in table 3 is analyzed
| Measure serum-concentration (U/mL) | Measure number of times | CV (%) in analyzing |
| 1.23 | 10 | 5.69 |
| 6.32 | 10 | 4.12 |
| 11.26 | 10 | 4.36 |
2. precision between analyzing
The kit of embodiment 4 is got three batches, and every batch of kit is all measured the serum of basic, normal, high three kinds of variable concentrations, 10 hole replicate determinations.Every part of serum obtains 30 concentration measured values, and referring to table 4, the coefficient of variation between statistical study is 5.20%～7.41%.
Precision test between table 4 is analyzed
| Measure serum-concentration (U/mL) | Measure number of times | CV (%) in analyzing |
| 1.23 | 30 | 6.69 |
| 6.32 | 30 | 7.41 |
| 11.26 | 30 | 5.20 |
(5) accuracy estimating
Add different amount HBeAg standard items in 2 routine pooled serum samples, the serum that forms 3 concentration levels adds sample, and the additive volume is less than 10% of cumulative volume.Detect concentration of specimens, by following formula calculate recovery rate.This method serum matrix recovery is between 90-110%.Data are referring to table 5.
R: the recovery;
V: the volume that adds standard solution;
V
0: the volume of people source sample;
C: people source sample adds the detectable concentration behind the standard solution;
C
0: the detectable concentration of people source sample;
Cs: the concentration of standard solution.
Table 5 accuracy estimating-interpolation recovery experiment data
(6) kit Evaluation on specificity
To kit specificity check be choose might cross reaction with the hepatitis B virus e antigen measured value the HBsAg positive sample, measure with this method.The results are shown in Table 6, this law and HBsAg no cross reaction.
The experiment of table 6 specificity
(7) correlativity evaluation
Chemical luminescence reagent kit with kit and Diasorin company detects simultaneously to 100 parts of human serum samples.Its testing result is referring to accompanying drawing 3, take the serum HBeAg concentration of the survey of the inventive method as horizontal ordinate, result take Diasorin company kit measurement does regretional analysis as ordinate, and dependent equation is: y=-0.01076+1.0084x, related coefficient is: 0.9938.Learn by statistics result and show, this method is good with external kit clinical sample measured value correlativity.
(8) Evaluation of Thermal Stability
Kit is carried out respectively 4 ℃ of 12 months and 37 ℃ of stability experiments of 7 days, the result show kit standard items luminous intensity variation, batch in and the indexs such as betweenrun precision, accuracy all within normal range, the kit term of validity can reach 12 months.
Above-described embodiment only is explanation technical conceive of the present invention and characteristics; its purpose is to allow the personage who is familiar with technique can understand content of the present invention and according to this enforcement; can not limit protection scope of the present invention with this; all equivalences that Spirit Essence is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (10)
1. the nano magnetic particulate chemistry luminescence assays kit of a hepatitis B virus e antigen, described kit comprises:
The first reagent: the solution that contains fluorescein-labeled hepatitis B virus e antigen antibody;
The second reagent: the solution that contains the hepatitis B virus e antigen antibody of alkali phosphatase enzyme mark;
Magnetic separating agent: the suspending liquid that contains the magnetic particle of coated fluorescein antibody.
2. the nano magnetic particulate chemistry luminescence assays kit of hepatitis B virus e antigen according to claim 1, it is characterized in that: the hepatitis B virus e antigen antibody of described alkali phosphatase enzyme mark is connected and composed by crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester and 2-imino group sulfane hydrochloride by alkaline phosphatase and hepatitis B virus e antigen antibody.
3. the nano magnetic particulate chemistry luminescence assays kit of hepatitis B virus e antigen according to claim 1 and 2, it is characterized in that: the concentration of the fluorescein-labeled hepatitis B virus e antigen antibody in described the first reagent is 0.5 ~ 1 μ g/mL, and the pH of described the first reagent is 7-9; The concentration of the hepatitis B virus e antigen antibody of the alkali phosphatase enzyme mark in described the second reagent is 0.5 ~ 1 μ g/mL, and the pH of described the second reagent is 7-9.
4. the preparation method of the nano magnetic particulate chemistry luminescence assays kit of a hepatitis B virus e antigen as claimed in claim 3; the step that it comprises the suspending liquid of the solution for preparing respectively the described solution that contains fluorescein-labeled hepatitis B virus e antigen antibody, the described hepatitis B virus e antigen antibody that contains alkali phosphatase enzyme mark and the described magnetic particle that is coated with fluorescein antibody is characterized in that: the preparation process of the solution of the described hepatitis B virus e antigen antibody that contains alkali phosphatase enzyme mark is as follows:
1. with after room temperature leaves standstill in the hepatitis B virus e antigen antibody adding crosslinking chemical 2-imino group sulfane hydrochloride solution, add glycine solution, room temperature leaves standstill again, collects the hepatitis B virus e antigen antibody after activating, and saves backup under 2 ~ 8 ℃ again;
2. the alkaline phosphatase enzyme solutions is added crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill, and collects the alkaline phosphatase after activating, and saves backup under 2 ~ 8 ℃;
3. with above-mentioned steps 1. the alkaline phosphatase of the hepatitis B virus e antigen antibody after the gained activation after 2. gained activates with step mix, leave standstill reaction, make the hepatitis B virus e antigen antibody that generates alkali phosphatase enzyme mark, after reaction finishes, with reactant liquor Supperdex200 gel-purified post purifying, damping fluid adjustment concentration and the pH value selecting to have proper pH value namely get described the second reagent;
Wherein, the purity of described hepatitis B virus e antigen antibody, described alkaline phosphatase is all more than or equal to 95wt%, and the specific activity of described alkaline phosphatase surpasses 1000u/mg.
5. preparation method according to claim 4, it is characterized in that: step 1. in, get hepatitis B virus e antigen antibody, add the dissolving of coupling agent 2-IT solution, room temperature leaves standstill 10min ~ 30min, adds glycine solution, room temperature leaves standstill 2 ~ 10min, with G-25 gel-purified post desalination, collect the hepatitis B virus e antigen antibody after activating, save backup in 2-8 ℃.
6. according to claim 4 or 5 described preparation methods, it is characterized in that: step 2. in, get concentration more than or equal to the alkaline phosphatase enzyme solutions of 5mg/mL, add 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill 20 ~ 40min, with G-25 gel column desalination, collect the rear alkaline phosphatase of activation, save backup in 2-8 ℃.
7. preparation method according to claim 4, it is characterized in that: the preparation method of described the first reagent is as follows: the pH that preparation contains fluorescein is 9 ~ 10 damping fluid, then the molecular proportion according to fluorescein and hepatitis B virus e antigen antibody is the ratio of 20 ~ 200:1, be 9 ~ 10 damping fluid with the described pH that contains fluorescein with the pH of hepatitis B virus e antigen antibody be that 9 ~ 10 damping fluid mixes, behind the mixing, room temperature leaves standstill reaction, then reactant liquor is separated by the G-25 gel column, remove free fluorescein, obtain containing the solution of fluorescein-labeled hepatitis B virus e antigen antibody, then adjust concentration and pH with the damping fluid with proper pH value, namely get the first reagent.
8. preparation method according to claim 4, it is characterized in that: the preparation method of described magnetic separating agent is as follows: make the magnetic particle that contains the carboxyl reactive group and fluorescein antibody in the presence of the coupling agent carbodiimide, room temperature reaction 2 ~ 18 hours, reaction finishes, magnetic separates, remove supernatant, adjust pH and concentration with the damping fluid with proper pH value, namely get described magnetic separating agent; Wherein said magnetic particle has superparamagnetism, and its diameter is 0.5 ~ 2 μ m, on every gram magnetic particle with the content of carboxyl reactive group more than or equal to 0.4mmol; Described fluorescein antibody is monoclonal antibody or polyclonal antibody, and purity is more than or equal to 90wt%, and dilution is tired greater than 1:100 ten thousand.
9. according to claim 4 or 7 or 8 described preparation methods, it is characterized in that: described damping fluid with proper pH value is the TRIS damping fluid that contains 0.5% bovine serum albumin(BSA), pH8.0.
10. the described kit of each claim is used for the quantitative detection method that detects of hepatitis B virus e antigen be is characterized in that in the employing claim 1 ~ 3, may further comprise the steps:
(1) immune response: add sample to be tested stoste in detector tube, add successively the first reagent and the second reagent, mixing carries out the incubation first time under 25 ~ 40 ℃, then add the magnetic separation agent, and mixing carries out the incubation second time under 25 ~ 40 ℃;
(2) washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add cleaning fluid, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant;
(3) add substrate solution and detect luminous intensity: in detector tube, add the chemical luminous substrate of alkaline phosphatase enzymatic, remove magnetic field, fully detect luminous intensity values behind the suspendible.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550172.7A CN103048454B (en) | 2012-12-18 | 2012-12-18 | Nano magnetic particulate chemistry luminescent assay kit of a kind of hepatitis B virus e antigen and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550172.7A CN103048454B (en) | 2012-12-18 | 2012-12-18 | Nano magnetic particulate chemistry luminescent assay kit of a kind of hepatitis B virus e antigen and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103048454A true CN103048454A (en) | 2013-04-17 |
| CN103048454B CN103048454B (en) | 2015-08-26 |
Family
ID=48061168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210550172.7A Active CN103048454B (en) | 2012-12-18 | 2012-12-18 | Nano magnetic particulate chemistry luminescent assay kit of a kind of hepatitis B virus e antigen and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103048454B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105463025A (en) * | 2015-11-26 | 2016-04-06 | 广西医科大学 | Technical method of using bioactive quantum dot nano-carrier for RNA interference |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101592663A (en) * | 2008-05-30 | 2009-12-02 | 北京科美东雅生物技术有限公司 | Hepatitis B e antigen magnetic particle chemiluminescent immunoassay kit and preparation method thereof |
| CN101750498A (en) * | 2009-10-16 | 2010-06-23 | 北京科美东雅生物技术有限公司 | Magnetic immunochromatographic test strip for detecting hepatitis B e antigen and preparation method thereof |
| CN101975859A (en) * | 2010-09-13 | 2011-02-16 | 北京倍爱康生物技术有限公司 | Magnetic microparticle separation chemiluminescent immunoassay detection method for hepatitis B virus surface antigen |
| WO2012019107A1 (en) * | 2010-08-05 | 2012-02-09 | Abbott Point Of Care Inc. | Magnetic immunosensor and method of use |
| WO2012019104A1 (en) * | 2010-08-05 | 2012-02-09 | Abbott Point Of Care Inc. | Immunoassay method and device with magnetically susceptible bead capture |
-
2012
- 2012-12-18 CN CN201210550172.7A patent/CN103048454B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101592663A (en) * | 2008-05-30 | 2009-12-02 | 北京科美东雅生物技术有限公司 | Hepatitis B e antigen magnetic particle chemiluminescent immunoassay kit and preparation method thereof |
| CN101750498A (en) * | 2009-10-16 | 2010-06-23 | 北京科美东雅生物技术有限公司 | Magnetic immunochromatographic test strip for detecting hepatitis B e antigen and preparation method thereof |
| WO2012019107A1 (en) * | 2010-08-05 | 2012-02-09 | Abbott Point Of Care Inc. | Magnetic immunosensor and method of use |
| WO2012019104A1 (en) * | 2010-08-05 | 2012-02-09 | Abbott Point Of Care Inc. | Immunoassay method and device with magnetically susceptible bead capture |
| CN101975859A (en) * | 2010-09-13 | 2011-02-16 | 北京倍爱康生物技术有限公司 | Magnetic microparticle separation chemiluminescent immunoassay detection method for hepatitis B virus surface antigen |
Non-Patent Citations (2)
| Title |
|---|
| 杨汉春，等: "《动物免疫学》", 29 February 1996, article "荧光素标记" * |
| 郭洪，等: "i2000化学发光分析仪检测乙型肝炎病毒标志物的应用", 《中华医院感染杂志》, vol. 21, no. 6, 20 March 2011 (2011-03-20), pages 1276 - 1278 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105463025A (en) * | 2015-11-26 | 2016-04-06 | 广西医科大学 | Technical method of using bioactive quantum dot nano-carrier for RNA interference |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103048454B (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103063851B (en) | Free triiodothyronine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof | |
| CN103063845A (en) | Nanometer magnetic particle chemiluminiscence kit, preparation method and detection method of hepatitis B virus surface-antibody | |
| CN103901203A (en) | Chemiluminescence quantitative detection kit for procalcitonin, and preparation method and detection method thereof | |
| CN103048452B (en) | Nanometer magnetic particle chemiluminiscence determination kit for antigen CA125 relating to tumor, as well as preparation method and determining method of same | |
| CN103364568B (en) | Laminin nano-magnetic particle chemiluminescent immunity quantitative detection kit and preparation method thereof | |
| CN102998467B (en) | β human chorionic gonadotrophin magnetic microparticle chemiluminescence immune quantitative detection reagent box and preparation method thereof | |
| CN110726841B (en) | Method for detecting veterinary drug residues based on enzymatic click reaction signal amplification magnetic relaxation time immunosensor | |
| CN103592445A (en) | Kit for detecting procalcitonin | |
| CN105181680B (en) | A kind of Beads enrichment chemical luminous immune detection method of melamine | |
| CN103076455B (en) | Quantitative detection serum amyloid A protein kit and Synthesis and applications thereof | |
| CN103278651A (en) | Kit for chemiluminescence immunity quantitative detection of MYO (myohaemoglobinnano) nano magnetic particle and preparation method of kit | |
| CN105467122A (en) | Kit and method for detection of thyroid peroxidase antibody | |
| CN104316679B (en) | The application of hyperbranched polyglycidyl ether decorated nanometer magnetic microsphere in chemiluminescence immune assay | |
| CN103048446B (en) | Luteinizing hormone nano-magnetic particle chemiluminescence assay kit and preparation method thereof and assay method thereof | |
| CN104198721B (en) | The preparation of a kind of silica-based magnetic bead bond of GP73 (GP73) antigen and application | |
| CN103048476A (en) | Thyroxine nanometer magnetic particle chemiluminiscence determinstion kit as well as preparation method and detection method thereof | |
| CN103048477B (en) | Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same | |
| CN102998466A (en) | Quantitative detection kit combining magnetic particles with chemiluminescence immunoassay for growth hormone (GH), and preparation method of kit | |
| CN103048453B (en) | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof | |
| CN103018465A (en) | Human cystatin C chemiluminescence quantitative detection method | |
| CN103823064B (en) | A kind of vomitoxin immue quantitative detection reagent box and using method thereof | |
| CN1963512A (en) | Chemiluminescence method for qualitative and quantitative detection of hepatitis B virus | |
| CN103018445A (en) | Chemiluminiscence immunoassay quantitative detection kit for saccharide antigen 50 magnetic particles and preparation method thereof | |
| CN106324254A (en) | Anti-insulin antibody detection kit and detection method thereof | |
| CN103063852B (en) | Free thyroxine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 building C6 No. 218 Patentee after: Jiangsu Hao Bo biomedical Limited by Share Ltd Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 building C6 No. 218 Patentee before: Suzhou Haooubo Biopharmaceutical Co., Ltd. |